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ABSTRACT Here are summarized data supporting that adrenomedullin (AM) is a multifunc-
tional factor involved in the complex regulatory mechanisms of mammalian development. During
rodent embryogenesis, AM is first expressed in the heart, followed by a broader but also defined
spatio-temporal pattern of expression in vascular, neural, and skeletal-forming tissues as well as in
the main embryonic internal organs. AM pattern of expression is suggestive of its involvement in
the control of embryonic invasion, proliferation, and differentiation processes, probably through
autocrine or paracrine modes of action. AM levels in fetoplacental tissues, uterus, maternal and
umbilical plasma are highly increased during normal gestation. These findings in addition to other
physiological and gene targeting studies support the importance of AM as a vasorelaxant factor
implicated in the regulation of maternal vascular adaptation to pregnancy, as well as of fetal and
fetoplacental circulations. AM is also present in amniotic fluid and milk, which is suggestive of
additional functions in the maturation and immunological protection of the fetus. Altered expres-
sion of AM has been found in some gestational pathologies, although it is not yet clear whether this
corresponds to causative or compensatory mechanisms. Future studies in regard to the distribution
and expression levels of the molecules known to function as AM receptors, together with data on the
action of complement factor H (an AM binding protein), may help to better define the roles of AM
during embryonic development. Microsc. Res. Tech. 57:40–54, 2002. © 2002 Wiley-Liss, Inc.
INTRODUCTION: MOLECULAR SIGNALS
IN DEVELOPMENT
Morphogenesis of multicellular organisms is highly
dependent on cellular interactions mediated through
secreted or membrane-displayed factors. These signals
influence neighbouring cells to modulate their develop-
mental fate through the regulation of the expression of
the relevant genes. In the last decades, Developmental
Biology has accumulated information on a variety of
secreted factors that are involved in the control of the
highly synchronized processes that occur during em-
bryogenesis. The local autocrine-paracrine effect of a
given factor on the neighboring cells is not the only way
of action for these molecular signals. The relevance of
the changes in the concentration levels while the factor
diffuses away from its source has also been repeatedly
demonstrated. This gradual distance-depending effect
of a signalling molecule over its target cell, together
with the variety of factors influencing each cell at a
given time point, and the positive and negative feed-
back loops that each signal provokes, makes the control
of gene expression during embryogenesis a very com-
plex field, as any cellular response is the effect of a
multifactorial cause. Even if the response of isolated
cells to a single factor may be known for a given cell
type, the integration of cellular responses to a set of
multiple signals and the effects due to cell-cell interac-
tion in the context of a forming organ are still not well
understood (Fraser and Harland, 2000). In any case,
the pursuit of new players of developmental control
continues. In mammalian embryogenesis, an increas-
ing number of secreted peptides have been shown to be
implicated in the long-term modulation of growth, dif-
ferentiation, cell migration, and cell death (Nilsen-
Hamilton, 1990). The present review summarizes the
data supporting that Adrenomedullin (AM) and its re-
lated peptide the proAM N-20 peptide (PAMP), are
growth factors potentially involved in the complex reg-
ulatory mechanisms of mammalian development.
ADRENOMEDULLIN IN MAMMALIAN
DEVELOPMENT
The expression of AM has been described in a variety
of adult animal and human tissues, including heart,
adrenals, brain, kidney, pancreas, aorta, lung, and
brain- and lung-derived tumors (Cameron and Flem-
ing, 1998; Cuttitta et al., 1999; Miller et al., 1996;
Montuenga et al., 1997; Washimine et al., 1995). These
observations, together with the data linking AM to
growth control in normal and tumor cells prompted us
to investigate the possible role of AM on embryogenesis
(Montuenga et al., 1997, 1998). Although the localiza-
tion of AM in adult mammalian tissues and human
neoplasms has already been the object of some studies,
and the role of AM in normal and pathological physi-
ology is now being clarified, the functional relevance of
AM during embryogenesis is still obscure. Our studies
showing a broad expression of AM in many forming
organs of mouse and rat embryos support a strong
involvement of AM during the embryonic and fetal
periods. In those studies, we analyzed AM expression
in mouse (E8–E16) and rat (E10–E18) development by
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means of molecular, biochemical, and histochemical
techniques.
In the following, we will summarize the current lit-
erature on the expression of AM in developing mam-
mals. First, we will comment on studies related to the
expression of AM in mouse and human placenta and
other structures at the early developmental stages.
Secondly, we will review data with regard to the ex-
pression of proAM-derived peptides during mouse and
rat morphogenesis and organogenesis. Most of the data
that we will present are derived from our original stud-
ies on mouse and rat embryos (Montuenga et al., 1997,
1998). Other authors have subsequently published a
number of data confirming our results and this will
also be discussed. Finally, studies on the levels of AM
in normal pregnancy and changes of AM levels in some
pregnancy-related pathologies will be reviewed.
AM IN EARLY DEVELOPMENTAL STAGES
AM in Fetoplacental Tissues
The studies from our group demonstrated the pres-
ence of intense AM-like immunoreactivity in the prim-
itive placenta at early rodent embryogenesis (mouse
E8, rat E11) when low immunoreactive signal for AM is
found in the developing embryonic tissues (Montuenga
et al., 1997). Specifically, AM is expressed in embryonic
cells of the ectoplacental cone, with very prominent AM
protein and mRNA staining in trophoblast giant cells
(see Figs. 1–3). Immunocytochemical AM staining was
also present in maternal decidual cells, endodermal
cells lining the yolk sac, and to a lesser extent in the
chorionic plate. Using an in situ hybridization tech-
nique, the specific L1 AM receptor (Kapas et al., 1995)
mRNA was also localized to several cell types of the
developing placenta, again with distinct expression in
trophoblast giant cells (Fig. 4) (Montuenga et al., 1997).
Subsequently, a more detailed study of AM expression
at the peri-implantation stage was conducted (Yot-
sumoto et al., 1998), since AM was found to be one of
the genes highly expressed in a cDNA library from the
ectoplacental cone of 7 days postconception (d.p.c.)
mouse embryos. Confirming our previous data, AM
expression was mainly detected in trophoblast cells in
the ectoplacental cone, being most highly expressed in
trophoblast giant cells. Because of the timing of AM
expression in these cells (AM mRNA starts to be de-
tected at 6.5 d.p.c., peaks at 9.5 d.p.c., and falls to a
much lower levels after 10.5 d.p.c.), it was proposed
that AM may act on the blood vessels by pooling ma-
ternal blood in the implantation site, securing nutri-
tion and O2 at this early postimplantation period when
an efficient chorioallantoic placenta is not yet estab-
lished (Yotsumoto et al., 1998). These authors, how-
ever, did not find a detectable expression of the L1 AM
receptor in extraembryonic tissues by Northern blot
analysis. Different sensitivity levels of Northern blot
and in situ hybridization techniques could be claimed
as the cause for the discrepancy with our results. How-
ever, the functional response of the L1 receptor (Kapas
et al., 1995) or its human homologue (Ha¨nze et al.,
1997) as AM receptors has recently been questioned
(Kennedy et al., 1998), and thus caution is needed with
regard to this piece of data in placental tissues. The
expression of other molecules known to function as AM
receptors, such as RDC-1 (Kapas and Clark, 1995),
CRLR/Receptor activity modifying protein (RAMP)2
and CRLR/RAMP3 (Chang et al., 1993; McLatchie et
al., 1998; Njuki et al., 1993), has not been studied
specifically in rodent placental tissues and, therefore,
awaits future investigations.
Likewise, human placental tissues have also been
found to express AM protein and mRNA. Within hu-
man placenta at term, AM is localized primarily in
extravillous trophoblast cells and in the syncytiotro-
phoblast, but is also present in endothelial cells of
villous blood vessels and in maternal decidual cells (Di
Iorio et al., 1998c; Kanenishi et al., 2000, 2001; Macri
et al., 1998; Marinoni et al., 1998). Occasionally, im-
munocytochemical staining for AM has also been re-
ported in cytotrophoblast cells and in the mesenchyma
and inflammatory cells within the villi (Kanenishi et
al., 2001; Macri et al., 1998). The fetal membranes,
and, more specifically, the epithelium of the amniotic
membrane, also show high levels of AM and its mRNA
(Kanenishi et al., 2000, 2001; Kobayashi et al., 2000;
Macri et al., 1996b; Makino et al., 1999c). The pattern
and intensity of AM immunoreactivity in the first tri-
mester human placenta and fetal membranes were re-
ported to be similar to that in term pregnancy (Macri et
al., 1996a; Kanenishi et al., 2001), suggesting that AM
secreted from these sites might play an important role
in the maintenance of normal pregnancy throughout
gestation. Similarly to the above-mentioned situation
in rodents, there is still limited information about the
expression of the different AM receptors in human
placenta. The mRNA for the human homologue to the
rat L1 AM receptor has been localized to first trimester
trophoblasts by in situ hybridization (Macri et al.,
1998), and also discrete expression was found in pla-
cental tissues by Northern blot analysis (Ha¨nze et al.,
1997). Both human RAMP2 and RAMP3 mRNA have
also been shown to be abundantly represented in hu-
man placenta as assessed by Northern blot analysis
(McLatchie et al., 1998). Further investigation for cell-
specific localization of the different AM receptor types
in human placenta, together with parallel correlation
with AM-binding and functional studies, are still
needed to better define the possible functions of AM in
this organ.
Successful mammalian embryonic development is
obviously dependent first on the synchronized develop-
ment of the fetoplacental vasculature, and subse-
quently on the maintenance of an adequate placental
vascular tone to achieve sufficient gas and metabolite
interchange between maternal and fetal circulations.
In fact, the above-mentioned expression of AM in the
villous mesenchyma together with the AM reported
angiogenic properties (Nikitenko et al., 2000; Zhao et
al., 1998), are suggestive of a possible role of this pep-
tide in placental vasculogenesis at the early postim-
plantation stages. Because the placenta lacks auto-
nomic innervation, the maintenance of an adequate
uteroplacental perfusion is regulated mainly by sys-
temic blood pressure changes through the action of
both circulating and locally released vasoactive agents
(Jaffe, 1998; Macara et al., 1993), keeping the placental
vasculature in a state of near-maximal dilatation. It is
noteworthy that the content of immunoreactive AM in
placentas (117.7  7.8 pg/mg wet tissue) and fetal
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Fig. 1. Mouse E9. Primitive placenta and embryo immunostained
for AM. 13.
Fig. 2. Mouse E9. Nonradiaoactive in situ hybridization for AM
mRNA in the mouse placenta showing strongly positive giant tropho-
blastic cells. 100.
Fig. 3. Mouse E9. Giant trophoblastic cells of the mouse placenta
immunostained for AM. 250.
Fig. 4. Mouse E8. In situ hybridization staining for the L1 AM
receptor in the mouse primitive placenta. 50.
Fig. 5. Mouse E11. Section of the whole embryo immunostained
for AM. Box: see Figure 6 legend. 5.
Fig. 6. Mouse E11. Detail of developing heart in a region similar to
box in Figure 5. Atrium and ventricle are positive, whereas the liver
primordium is not stained. Cardiomyocytes but not endocardial cells
are positive for AM. 120.
Figs. 7–9. Mouse E11–E16. Expression of AM during maturation
of dorsal root ganglia and cartilage. Condensing mesenchymal cells at
the early stages of chondrogenesis are negative, as well as the young
neurons of the early dorsal root ganglia (Fig. 7). Detectable levels of
AM increase in later stages both in chondrocytes (Fig. 8) and neurons
(Figs. 8,9). Fig. 7, E11 270; Fig. 8, E12 200; Fig. 9, E16 150.
Fig. 10. Detail of the mouse E16 forming pancreas. Note positive
primitive islets budding off the ducts in top right corner. 400.
Fig. 11. Rat E16 kidney. Metanephric duct and derived ducts are
positively stained for AM. Top right: Immunostained tissue of the
adrenal gland can also be observed. 50.
Fig. 12. Rat E18. In situ hybridization for AM mRNA in the
kidney. Apart from the ducts, some cells of the differentiating glomer-
uli express AM mRNA. 50.
membranes (168.7  2.3 pg/mg wet tissue) is compara-
ble to the AM concentration in adrenal medulla
(157.3  74.4 pg/mg wet tissue) (Marinoni et al., 1998),
thus being much higher than that found in other hu-
man tissues examined (Kim, 1999; Kitamura et al.,
1998). Since AM has potent vasodilator properties
(Kitamura and Eto, 1997; Letizia et al., 1999), the
expression of AM in placenta and fetal membranes,
together with high AM levels in pregnant uterus (Up-
ton et al., 1997), maternal plasma, and amniotic fluid
(Di Iorio et al., 1997b, 1999; Kanenishi et al., 2001),
makes it likely that during normal pregnancy AM may
contribute to the regulation of the placental vascular
tone. Very interestingly, using isolated perfused pla-
cental cotyledons, AM was shown to cause vasodilata-
tion of fetoplacental vasculature previously constricted
with a thromboxane sympathomimetic (Hoeldtke et al.,
2000), thus providing physiological support to the pos-
sible vasodilatory effect of AM in the regulation of
fetoplacental vascular tone. However, since supra-
physiological concentrations of AM were needed to pro-
duce this effect in vitro, AM was proposed to exert its
putative vasodilatory action in the placenta acting lo-
cally through specific receptors in endothelial and vas-
cular smooth muscle cells rather than as a circulating
hormone (Hoeldtke et al., 2000).
Finally, it is of interest that calcitonin—a peptide
belonging to the same family as AM, although with
lower homology degree than CGRP or amylin (Wimala-
wansa, 1997)—is markedly induced in the pregnant rat
uterus during implantation (Ding et al., 1994). In fact,
the loss of calcitonin gene expression upon antisense
treatment is accompanied by a severe impairment in
the implantation of embryos (Zhu et al., 1998). Thus, it
looks as if the presence and function of at least some
members of the calcitonin family of peptides (calcitonin
and AM) in the endometrium and/or placental tissues
may play important roles in implantation and in the
maintenance of normal placental function.
Expression of AM in In Vitro Models
of Early Embryo
Human placental development depends critically on
the differentiation of the placentas specialized epithe-
lial cells, termed trophoblasts (Cross et al., 1994;
Fisher and Damsky, 1993). Two natural differentiation
fates exist for this cell type: in one, trophoblasts remain
in flotating villi and fuse to form the highly specialized
syncytiotrophoblast layer that covers the flotating cho-
rionic villi; being in direct contact with maternal blood,
the syncytiotrophoblast contributes to gas, nutrient,
and waste exchange for the fetus. Alternatively, a sub-
set of trophoblast cells in anchoring villi proliferate and
generate a multilayered column of extravillous tropho-
blasts. These extravillous trophoblasts later migrate to
the uterine wall and invade as far as the first third of
the myometrium, inducing remodelling of the spiral
arterioles to produce the low-resistance vascular sys-
tem that is essential for fetal growth (Genbacev et al.,
2000).
One of the feature characteristics of first trimester
human trophoblast cells is that, similarly to malignant
tumor cells, they are inherently invasive (Fisher et al.,
1989; Librach et al., 1991; Yagel et al., 1988). In fact,
these invasive trophoblasts exhibit some of the molec-
ular mechanisms of invasion typical of tumoral cells,
such as production of significant levels of type IV col-
lagenase and laminin required for basement mem-
brane invasion (Librach et al., 1991; Yagel et al., 1988),
and expression of matrix metalloproteinases and plas-
minogen activators (Harvey et al., 1995). However, un-
like tumoral cells, invasive trophoblasts in vivo do not
have the ability for unlimited growth or metastasis, but
rather their invasiveness is under strict control both in
a spatial and temporal manner. This control seems to
be dependent on a repertoire of growth factors largely
produced by decidual cells of the uterus, and to a minor
extent also derived from the trophoblasts themselves.
For instance, transforming growth factor  (TGF)
seems to be a key mediator against trophoblast inva-
sion in vivo by inducing tissue inhibitor metallopro-
teinases (TIMPs) production in the decidua as well as
in trophoblasts (Graham and Lala, 1991). Interest-
ingly, AM expression in maternal decidual cells as well
as in trophoblast giant cells in mouse placenta has
been found to colocalize with that of TGF1 (Montu-
enga et al., 1998); this concomitant expression may be
of relevance if these two factors have opposite modula-
tory properties to exert on the invasiveness of tropho-
blast cells. In the same sense, other factors such as
leukemia inhibitory factor (LIF) and epidermal growth
factor (EGF), which are produced by the uterine endo-
metrial glands and luminal epithelium, respectively,
have also been found to differentially regulate matrix
metalloproteinases and plasminogen expression in
peri-implantation blastocysts, thus modulating inva-
siveness at the implantation stages (Bass et al., 1994;
Harvey et al., 1995).
The differentiation of human placental trophoblast
cells into a syncitium has been simulated in an in vitro
culture system by the action of EGF (Morrish et al.,
1987, 1996). Other factors such as colony stimulating
factor-1 (CSF-1) and granulocyte-macrophage colony
stimulating factor (GM-CSF) also stimulate (Garcı´a-
Lloret et al., 1994; Morrish et al., 1987), whilst TGF1
inhibits (Morrish et al., 1991) in vitro biochemical and
morphological syncytiotrophoblast differentiation. In-
terestingly, using a subtractive hybridization proce-
dure, AM was found to be one of the genes whose
expression was increased by EGF-induced differentia-
tion (Morrish et al., 1996). It is not known, however,
whether AM might represent a genetic indicator of
EGF action in the differentiating trophoblast or a by-
product of the differentiated phenotype.
In addition to its role in nutrient, gas, and waste
exchange, the syncytiotrophoblast is also considered to
be an endocrine tissue implicated in the synthesis and
secretion of steroid and peptide hormones (Cross et al.,
1994; Morrish et al., 1987; Yagel et al., 1989). In adults,
AM has been found to influence the secretion rate of
several hormones such as insulin, adrenocorticotropin,
catecholamine, aldosterone, and renin (Hirata et al.,
1995; Katoh et al., 1995; Martı´nez et al., 1996; Samson
et al., 1995; Yamaguchi et al., 1995). The AM expressed
in the syncytiotrophoblast may also have a similar role
as a hormone secretion regulator.
There are no studies available regarding the pres-
ence and function of AM in early embryonic cells. AM
and PAMP have been reported to be biologically active
in some embryonic carcinoma cell lines, which have
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similar properties to pluripotent cells of the inner mass
of the blastocyst (Moody et al., 2000). In binding stud-
ies using the teratocarcinoma PA-1 cell line, AM
seemed to act through CGRP1 type receptors, stimu-
lated adenylyl cyclase, c-fos mRNA expression, and cell
proliferation. PAMP, on the contrary, bound to a dif-
ferent class of receptors, and inhibited or reversed the
actions caused by AM (Moody et al., 2000). Likewise,
the authors suggested that PAMP might also be a
physiological antagonist of AM in vivo having a some-
how compensatory role for AM during embryonic de-
velopment, although this hypothesis remains to be
proven.
AM IN MORPHOGENESIS AND
ORGANOGENESIS
Table 1 summarizes our data on mouse immunore-
activity for AM embryos (E8–E16). In situ hybridiza-
tion for AM mRNA shows a parallel anatomical distri-
bution. Although not shown here, RT-PCR and North-
ern blot analyses of isolated total mRNA both in rat
and mouse embryonic tissues confirmed the presence of
AM and the AM receptor (L1) message (Montuenga et
al., 1997, 1998). As a general outline, we have shown
that the pattern of appearance and distribution of AM
immunoreactivity in the rat is very similar to that of
the mouse, but happens 1.5–2 days later in develop-
ment. Nevertheless, some differences are found be-
tween the two species. In general, the later stages of
development of rat embryos showed higher levels of
AM-immunoreactivity than the equivalent stages in
the mouse. Here is presented mainly the data corre-
sponding to the mouse embryo and, when a significant
variation exists, the peculiarities found in rat develop-
ment.
Cardiovascular System
The first organ to express AM in the developing
mouse embryo is the forming heart. On day 8, the walls
of the common atrial and ventricular chambers of the
primitive heart show slight immunoreactivity for AM.
In the E9 embryo, the cardiac tube is markedly immu-
nostained with the same antibodies. Throughout all
the following stages of the mouse development, the
developing heart is the organ that shows higher levels
of immunoreactivity (Figs. 5,6). The myocytes of both
atrial and ventricular walls, including the elaborate
trabeculae formed around E10 in the ventricular cham-
ber, strongly express AM. The differentiating smooth
muscle fibers that are found in the large arteries at E11
are also very immunoreactive for AM. Cormier-Regard
et al. (1998), using the technique of differential display,
reported that the AM gene was differentially expressed
in developing rat heart. The RT-PCR analysis per-
formed by these authors revealed that the level of AM
mRNA was significantly higher in adult ventricular
cardiac muscle as compared with embryonic day
17 ventricular cardiac muscle. As we also reported for
the mouse embryos, Cormier-Regard et al., showed
that the AM receptor mRNA (L1) was constitutively
expressed throughout development of the rat ventricu-
lar heart. In our studies in the embryonic rat, endothe-
TABLE 1. Tissue distribution of immunohistochemically detectable AM in mouse organogenesis1
Tissue Localization E8 E9 E10 E11 E12 E13 E14 E15 E16
Heart 1 2 3 3 3 3 3 3 3
Arterial vasculature 1 2 2 2 2 2 2
Central nervous system Brain 0 0 1 1 1 1 1 1 2
Pituitarv 1 ND ND 1 1 1
Choroid plexus 0/1 2 2 2 2 2 2
Peripheral nervous system Spinal cord 0 0 1 1 1 2 2 2 2
Dorsal root ganglia 0 0/1 1 2 2/3 3 3
Eye Retina 0 0 0 0/12 0/12
Ear Choclear epithelium 0 1 1 1 1/2 2
Skeletal structures Skeletal muscle 0 1 2 2 2 2
Precartilaginous blastema 0
Perichondrium 0 0 0 0/1 0 0
Chondrocytes 0 1 2 2 2 2
Hypertrophic cartilage 3 2 2
Osteoblasts 2 2 3
Skin 1 2 2 2 2 2
Whisker follicles 1 2 2 2
Intestine Epithelium 1 1 1 1 2
Muscle fibers 1 2 2 2 2
Liver Hepatocytes 0 0 0 1 1 1
Megakaryocytes 1 1 1 1 1 1
Thymus Cortex ND 0 0 0
Medulla ND 0 1 1
Lung Epithelial cells 0 1 1 1 13/04 13/14 03/24
Mesenchyma 0/1 0 1 1 1 1 1
Airway smooth muscle cells 0/1 1 1
Kidney Metanephric duct derivatives 0 2 2 2 2
Forming tubules 0 0 0 0 1
Glomeruli 0 0 0/15 15 15
Adrenal gland 1 2 2 2 2
1Staining intensity is ranked from 0 (no staining) to 3 (very intense staining). ND, not determined.
2Outer neuroblastic layer.
3Prospective respiratory system.
4Prospective bronchial system.
5Glomerular capillary and mesangial tufts.
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lial cells expressed AM earlier than in the mouse equiv-
alent stage and in a broader pattern. AM-immunore-
active endothelial cells could be found as early as the
E10 stage in the rat embryo and were also found in
some very small vessels such as the ones in developing
glomeruli at E16–17. In the developing mouse embryo,
the smaller blood vessels were less frequently stained
for AM.
Nervous System
At mouse E10, the neural tube starts producing AM-
like material. In this stage, the maturing cells of the
ventral horn of the spinal cord stain for AM. On E12
and the following days, the contrast between differen-
tiated stained and less differentiated unstained areas
of the central nervous system is clearer. From E12 on,
specific groups of neurons positive for AM can be ob-
served in the central nervous system, for example in
the mantle layer of the spinal cord. Neural crest–de-
rived dorsal root ganglia and their segmental nerve
trunks become increasingly immunostained from E11–
E12 onwards (Figs. 7–9). Throughout the rest of the
development, AM will be localized to the neuropil, in-
dividual or grouped neurons within the central nervous
system and the dorsal root ganglia (Figs. 8,9). A certain
segmental progression in the degree of staining of dor-
sal root ganglia is also detected within a given stage,
suggesting that AM expression goes in parallel with
sensory neuron maturation. A detailed map of the ex-
pression of AM in the adult rat has been already pub-
lished (Serrano et al., 2000) showing a widespread
presence of this peptide throughout the rat central
nervous system. Recently, the relevance of AM in eye
physiology has been shown (Taniguchi, 1999). Our data
on the developing eye also showed a discrete immuno-
cytochemical signal in the outer neuroblastic layer of
the retina at E14–E15. In situ hybridization showed
that the mRNA for AM is also present in the same cells.
Skeletal and Integumentary Tissues
AM-immunoreactive material and mRNA could be
detected in groups of mouse mesenchymal cells from
day 9. The expression of AM by the mesenchymal cells
seems to follow precise patterns of spatio-temporal dis-
tribution, as the degree of staining of this tissue varied
from one region to the other and during development.
The expression of AM in undifferentiated early mesen-
chymal cells may be relevant and deserves further
attention, especially after the numerous reports show-
ing the broad differentiation potential of mesenchymal
stem cells (Pittenger et al., 1999). In the E12–E13
stage, when the differentiation of the cartilaginous
skeleton proceeds from condensed mesenchyma/precar-
tilage towards more mature chondrocytic cells, AM-like
material starts to be expressed. Condensing mesenchy-
mal/precartilage cells are immunocytochemically neg-
ative for AM whereas maturing cartilage and hypertro-
phic cartilage cells are increasingly positive from
mouse E13. Osteoblasts of the developing bone are
consistently immunoreactive for AM. Interestingly,
Cornish et al. (1997) have shown that the addition of
AM increases [3H]-thymidine incorporation into cul-
tured neonatal mouse calvaria in a dose-dependent
way. Cornish et al. (1997) also show that AM increases
cell number and [3H]-thymidine incorporation in cul-
tures of fetal rat osteoblasts. The role of AM in bone
morphogenesis and repair deserves further detailed
studies, which could be very relevant to bone pathology
and therapeutics.
The striated muscle cells were also immunoreactive
for AM once they differentiated. This is particularly
evident between mouse E12 and E14, when the tongue
elongates and increases in volume and the striated
muscle fibers differentiate from the corresponding
myotubes. AM-like expression is observed in the outer
layer of the early skin, the periderm, from the E10
stage and increases its expression in the epidermal
cells of the more differentiated skin on day 14 and
throughout the whole developmental stages that fol-
low. AM mRNA and the mRNA for the L1 AM receptor
could also be found by in situ hybridization in the
forming skin. Martı´nez et al. (1997) have shown that
AM is an autocrine growth factor in human normal and
malignant keratinocytes, suggesting that the role of
AM present in the forming skin may also be related to
the control of proliferation of the nascent keratinocytes
during fetal skin formation. Both in the fetal mouse
and rat, the cells that form the outer layer of the
forming hair follicles are also immunostained for AM.
Embryonic Internal Organs
Apart from the heart, other internal organs express
AM in the mouse embryo. In the gut, development
progresses in a proximal to distal direction so that at
one time point different segments of the gut are at
various stages of maturation. Initially, when the lumen
of the gut is small and is lined by a pseudostratified
columnar epithelium, no AM staining is observed. In
E13, as the gut matures, AM expression is found in the
mesenchymal cells that will form the gut muscle layer.
From E14 onwards, the presence of AM in the epithe-
lium increases. In E16, the more differentiated simple
columnar intestinal epithelium shows expression of
AM located mainly in the apical region of the entero-
cytes. While the pancreatic primordia are initially neg-
ative for AM, at E14 a number of cells at the developing
pancreatic ducts become immunoreactive for AM (Fig.
10). These are the primordia of the endocrine islets,
budding off the ducts. The pattern of colocalization of
AM with the other pancreatic hormones has also been
followed during rat pancreatic development (Martı´nez
et al., 1998); it was found that at some point during
development, all the endocrine cell types express AM,
progressively evolving towards the adult pattern where
only the pancreatic polypeptide-cells contain a strong
immunoreactivity for AM. A clear AM staining for dif-
ferentiated hepatocytes was found in the liver of the
E17 rat embryo, which was less apparent in the equiv-
alent stage of mouse development. In the adult rat
liver, no AM immunostaining is usually found. In the
early developing mouse lung, there is no expression in
the airway epithelium and very little in the mesen-
chyma that surrounds it. On day 11–12, the epithelium
of the primordia of the bronchial tree shows incipient
staining that tends to concentrate in the apical regions.
In E13–E14 mouse embryos, lung mesenchymal ex-
pression of AM is present. In particular, the cells sur-
rounding the developing bronchi that will differentiate
into smooth muscle cells stain particularly strong.
Smooth muscle fibers of the forming arteries also seem
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to express high levels of AM-immunoreactive material
at this stage. In E15–E16 embryos, staining for AM is
also found in the epithelial cells of the forming airways.
Interestingly, Northern blot analysis of mRNA ex-
tracted from mouse fetal lung and gut show very high
levels of RAMP-2 (Husmann et al., 2000), which would
allow the signalling through AM, supporting our view
that autocrine and paracrine regulation via AM may
take place during gut and lung organogenesis. During
the formation of the kidney, the first AM expressing
cells are found at mouse E13–14/rat E16 in the epithe-
lium of the metanephric duct and later on in the met-
anephric collecting tubules, but not in the mesenchyma
from which primitive glomeruli forms (Fig. 11). AM
expression is found in the epithelium of the developing
nephrons at the S-shape body stage and, in the final
stages of development, in the endothelial cells of the
capillary and mesangial cell tufts of the developing
glomeruli (Fig. 12). AM-immunoreactive material can
also be found in the primordia of the adrenal glands
from mouse E13–14 or rat E16 (Fig. 11). The immuno-
reactivity is more prominent in the medulla than in the
cortex of the adrenal, as can be expected from the data
published for the adrenal gland in adult mammals. The
mRNA for AM follows the same pattern of distribution
at this stage.
Possible Roles of AM in Mammalian
Morphogenesis and Organogenesis
The results of our study and those of others strongly
indicate that AM-mediated signaling is present in a
large number of embryonic and extraembryonic cells
and tissues during mouse and rat development. In
these species, the onset of the increasing expression of
AM-like peptide and mRNA occurs at the early orga-
nogenesis period. Initially, it is restricted to limited
regions of the embryo, but seems to be present in most
of the tissues and organs in the final stages of devel-
opment. The widespread localization of AM that we
have just described and the known multifunctional
properties of the proAM derived peptides suggest that
during development AM may have multiple roles in a
variety of tissues and organs. Data concerning the lo-
calization of the L1 AM receptor (Montuenga et al.,
1997) and the expression of AM-related RAMPs in
some fetal organs (Husmann et al., 2000; Sexton et al.,
2001) give further support to the active role of AM
during development and suggest autocrine or para-
crine modes of action.
Our results on the localization of AM and the L1 AM
receptor, together with the available data on AM di-
verse functions, have led us to formulate the hypothe-
sis that AM could be involved in the regulation of
mammalian morphogenesis possibly through the con-
trol of cell proliferation, differentiation, and migration.
The mitogenic of AM properties of AM on normal and
malignant cells is thoroughly discussed by Cuttitta et
al. (see Part II of this special issue). One of the first cell
types on which the proliferative effect of AM was
shown was embryonic mouse fibroblasts (Withers et al.,
1996). Many reports coincide by showing that the mi-
togenic effects are dependent on a cAMP signal. In a
recent report, we have shown that AM binds to human
PA-1 teratocarcinoma cell lines and elicits a cAMP
response together with an increase in [3H]-thymidine
incorporation (Moody et al., 2000). AM has also been
found to be expressed and to have specific effects on
several lineages of embryonal, fetal, and neonatal ori-
gin, such as rat osteoblasts (Cornish et al., 1997), ro-
dent cardiomyocytes (Cormier-Regard et al., 1998; Tsu-
ruda et al., 1998), rat cardiac fibroblasts (Tsuruda et
al., 1999), and other embryonic fibroblasts (Coppock et
al., 1999; Isumi et al., 1998, 1999). Interestingly, in
some cell types, like mesangial and vascular smooth
muscle cells, AM seems to act also as an inhibitor of
proliferation, also through a cAMP-mediated signal.
A functional relationship between the expression of
AM and differentiation can be deduced by the anatom-
ical distribution of AM immunoreactivity and mRNA.
In many of the embryonic organs, AM expression
seems to correlate with the onset and progression of the
differentiation process. For example, in the formation
of the cartilaginous templates that precede bone, AM
and the AM L1 receptor seem to be expressed in the
more mature cell types in the chondrocyte lineage,
including the hypertrophic cells, while the condensing
mesenchymal cells that are present in the previous
stages express very low, if any, levels of the peptide and
its receptor (Fig. 7). Another example in which the
expression of AM seems to be associated with the de-
gree of differentiation is the neural tissue. While in the
early neural tube neither immunocytochemical signal
for AM nor mRNA of the ligand or the L1 receptor is
observed, later on AM is present in many of the differ-
entiated regions of the central nervous system. The
expression of AM in the neurons of the sensory ganglia
is also increased in the later stages of development
(compare Figs. 7 and 9), especially from the moment
when most of the dorsal root ganglia neurons are prob-
ably formed. Moreover, the well-established craneo-
caudal developmental delay in neuronal maturation of
the sensory ganglia clearly correlates with differences
in the levels of AM expression (unpublished data).
Finally, a possible role of AM in regulating cell mi-
gration is supported by the expression of this ligand
and the mRNA for the L1 AM receptor in migratory-
invasive cells of the embryo, such as the giant tropho-
blastic cells, the forming blood vessels, or the neural
crest–derived cells. AM has already been proposed as a
proangiogenic molecule (Nikitenko et al., 2000; Zhao et
al., 1998). Reported cell motility–related effects of AM
are the stimulation of liver stellate cell relaxation
through a cytoskeletal reorganization (Kawada and In-
oue, 1994), and the inhibition of angiotensin II-stimu-
lated glomerular mesangial and vascular smooth mus-
cle cell migration (Kohno et al., 1997, 1999).
The formation of organs during embryogenesis is
highly dependent on the sequential and time-regulated
expression of a number of growth factors (Nilsen-Ham-
ilton, 1994). The pattern of distribution of AM-like
immunoreactivity and its mRNA during murine devel-
opment is very similar to that of other well-established
peptide growth factors. As mentioned before, we have
also performed a detailed study comparing the distri-
bution of AM protein and mRNA with those of TGF1
in mouse and rat embryos (Montuenga et al., 1998).
Our study shows that the expression of TGF1 and AM
is regulated in a spatial and temporal manner, such
that overlapping patterns of expression occur in sev-
eral tissues at the same stage of development and in
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the same cellular location in rodent embryogenesis.
These data suggest that AM and TGF1 could be in-
volved in analogous functions in relation to the forming
of new tissues and organs. AM distribution also shows
some coincident locations with other active peptides
like platelet-derived growth factor (PDGF), the fibro-
blast growth factors, insulin-like growth factor (IGF)-I
and II, and the recently discovered cardiotrophin, a
member of the leukemia inhibitory factor/ interleu-
kin-6 family. On a comparative basis with the data
available on growth factors, AM seems to be the pep-
tide that is expressed in a larger variety of cells and
tissues throughout development, which suggests that
this peptide is an important requirement for develop-
ment to proceed in most organs.
AM is abundantly expressed in areas where strong
mesenchymal-epithelial interactions take place during
development, such as kidney, lung, tooth primordia,
and hair follicles. Other growth factors, such as IGF I
and II, TGF1 and 2, and PDGF are also expressed in
the developing kidney in a very specific spatial and
temporal pattern, as happens for AM (Hammerman,
1995). Nevertheless, apart from localization, no func-
tional data have been provided to support the relevance
of AM in these cell-to-cell cross-talk processes. Further
studies testing the effects of AM on the numerous
available in vitro models for experimental morphogen-
esis are required.
Expression of PAMP During
Embryonic Development
The expression of PAMP in the early embryo is still
a matter of discussion. All the data available to date on
the expression of PAMP in adult mammals show that
the concentration of this peptide in the plasma or in
tissues is always lower than that of AM. Consistent
with these data, our early studies (Montuenga et al.,
1997) showed a fainter immunoreaction for PAMP in
most embryonic tissues, suggesting a lower level of
expression as compared to AM.
AM Receptors and AM Binding Proteins
During Embryogenesis
Born et al. (pages 14–22, this issue) deal with the
issue of AM receptors and signal transduction. In any
case, the field of AM receptors is still open and a matter
of discussion, as several unrelated molecules have been
proposed (Hinson et al., 2000; Poyner, 1997) and recep-
tor activity modifying proteins are also involved (Sex-
ton et al., 2001). As is true for several other growth
factors involved in morphogenesis, such as PDGF or
the several TGFs/Bone Morphogenetic Proteins
(BMPs), AM ligand co-localizes with one of its putative
receptors (L1 receptor; Kapas et al., 1995) in a variety
of developing organs. Also, Northern blot analysis of
some mouse embryonic tissues have been found to
abundantly express RAMP2 (lung and gut), whereas
RAMP3 was mainly found in embryonic brain (Hus-
mann et al., 2000; Sexton et al., 2001), therefore offer-
ing the possibility of AM action in these organs with a
coexpressed CRLR receptor. These findings concerning
the expression of different AM receptors during embry-
onic development support the hypothesis that AM may
act locally in a short-range autocrine or paracrine
mode. Once the area of AM receptors and RAMPs is
settled, it will be very interesting to explore the devel-
opmental pattern of expression of every bona fide AM
receptor in order to compare its distribution with that
of the ligand. In this way, we will be able to understand
the possible autocrine and paracrine interactions con-
trolled by this peptide.
The recent discovery that the complement cascade
protein factor H is a specific binding protein for AM and
has functional modulatory properties for the action of
AM on target cells (Pı´o et al., 2001) may also be rele-
vant during development. In fact, factor H has been
detected in fetal serum and amniotic fluid during hu-
man pregnancy (Stabile et al., 1988), it has been found
to be synthesized by the amniotic membrane (Katz et
al., 1995) and human umbilical vein endothelial cells
(Brooimans et al., 1989), and is also present in fetal
kidneys (Timmerman et al., 1996). The binding pro-
teins provide an additional level of control via AM by a
high-affinity locally secreted factor. This protein may
modulate receptor activation by AM ligand as has been
shown in the case of the binding proteins for the BMP
and activin members of the TGF family of ligands.
Several TGF binding proteins are currently the object
of increasing interest in the context of vertebrate de-
velopment—follistain, noggin, and chordin—which are
particularly active in relation to the Spemann orga-
nizer, an area of the Xenopus embryo with endogenous
dorsal inducing activity (Smith, 1999). As a general
developmental concept, localized action of ligand inhib-
itory binding proteins can mask a group of cells from
the inductive activity of the ligand while allowing
nearby cells to respond. In this way, the same locally
secreted ligand may have opposite effects in the neigh-
bouring cells not only depending on the repertoire of
expressed receptors, but also on the presence of vari-
able concentrations of a diffusible inhibitory (or even
stimulatory) binding protein. The existence of this AM
binding protein may contribute to the regulatory ac-
tions of AM throughout embryogenesis.
In summary, there are still very sparse and limited
data about the role of AM and PAMP in embryogenesis.
Most of the assumptions are based on the sites of
expression and by analogy with other multifunctional
growth factors for which functional studies have been
already performed. In any case, the available knowl-
edge supports that AM may play an important role in a
variety of key processes in embryonic development,
namely in the control of growth, differentiation, and
invasion. Further functional evaluation, on the basis of
what is known through the distributional study, will
clarify the validity of this hypothesis.
CLINICAL ASPECTS RELATED TO THE
LEVELS OF AM IN NORMAL PREGNANCY
AND PATHOLOGICAL SITUATIONS
Normal Pregnancy AM Levels in Maternal
Plasma, Amniotic Fluid, Umbilical Cord
Plasma, and Milk
AM in Maternal Plasma. Different research
groups have shown elevated levels of AM in plasma of
pregnant women at term (from 3- to 5-fold increase), as
compared to levels in non-pregnant women or levels in
the early puerperium (Di Iorio et al., 1999; Kanenishi
et al., 2001; Kobayashi et al., 2000). Other vasoactive
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substances, such as endothelin, prostaglandin E2, and
prostacyclin, have also been reported to increase in
maternal plasma in a similar fashion (Brennecke et al.,
1985; Goodman et al., 1982; Mastrogiannis et al.,
1991). However, when comparing AM concentrations in
plasma throughout pregnancy, some investigators
have found no significant changes between different
periods (Di Iorio et al., 1999), whereas others have
reported increasing concentrations with advancing ges-
tation (Kanenishi et al., 2001), or significant increases
only in the third trimester (Kobayashi et al., 2000).
By use of a specific radioimmunoassay for the ma-
ture form of AM (amidated AM), Kamenishi et al.
(2001) also determined the ratio between mature and
total AM concentrations in maternal plasma through-
out gestation. This ratio was found to be highest in the
second trimester. Since the biological activity of ma-
ture AM has been reported to be 95% more potent than
the activity from the glycine-extended form (imma-
ture), this difference could be indicative of more pro-
found hypotensive effects of AM during the midgesta-
tional period (Kanenishi et al., 2001).
AM circulating in maternal plasma may derive from
maternal or fetoplacental tissues, although lack of cor-
relation between maternal plasma and amniotic fluid
AM concentrations does not support the placental ori-
gin. More likely, the placenta together with several
AM-producing maternal tissues [endothelial cells
(Sugo et al., 1994), corpus luteum (Abe et al., 2000),
pregnant uterus (Upton et al., 1997)], contribute to the
increased maternal plasma levels of AM during preg-
nancy.
AM in Amniotic Fluid. Interestingly, significantly
higher AM concentration has been found in amniotic
fluid as compared to maternal plasma at any gesta-
tional age (Di Iorio et al., 1999; Kanenishi et al., 2001).
The amniotic membrane, placenta, and the embryo
proper are candidate sources for these elevated levels
in the amniotic fluid (Di Iorio et al., 1999; Kanenishi et
al., 2001; Macri et al., 1996b). Both total AM concen-
tration in amniotic fluid (Di Iorio et al., 1999; Kane-
nishi et al., 2001), and the mature/total AM concentra-
tion ratio (Kanenishi et al., 2001) were significantly
increased in late gestation. Future studies should elu-
cidate the putative importance of this AM increase in
the amniotic fluid on fetal organ development and/or
maturation at this gestational period. Besides, AM has
also been shown to have antimicrobial activity (Allaker
et al., 1999; Walsh et al., 1998), and thus a protective
role of AM in the amniotic fluid preventing fungal or
bacterial infections during pregnancy has also been
proposed (Macri et al., 1996b).
AM in Umbilical Cord Plasma. High AM levels
have also been detected in umbilical cord plasma (Di
Iorio et al., 1997b, 1999; Hoeldtke et al., 1998), al-
though there are some discrepancies in the reported
data concerning arterial and venous AM concentra-
tions. Hoeldtke et al. (1998) found no significant differ-
ences between the umbilical arterial and venous
plasma levels of AM, which would be indicative of
neither net production nor net destruction of this pep-
tide within the placenta. In contrast, AM concentra-
tions were reported to be significantly higher in umbil-
ical vein than in artery (Di Iorio et al., 1999), which in
turn would favor the placental origin of AM in fetal
circulation. Consistent with the latter proposal, no sig-
nificant correlation was found between fetal and ma-
ternal AM plasma concentrations, thus supporting the
view that AM in umbilical plasma is not derived from
maternal circulation, but rather from the placenta (Di
Iorio et al., 1999).
Under normal conditions of pregnancy, important
physiological adaptations occur in the mother that en-
sure an adequate blood supply to the fetus. Peripheral
resistance, mean arterial pressure, and sensitivity to
vasopressor agents are reduced, whereas cardiac out-
put, heart rate, and blood volume are increased (Car-
billon et al., 2000; Macara et al., 1993). AM has been
characterized as a key player in the modulation of
blood pressure and vascular homeostasis in adult life
through its well-documented vaxorelaxant effects
(Kitamura and Eto, 1997; Letizia et al., 1999; Nuki et
al., 1993). In this sense, it has also been found that
patients with hypertension and renal failure show
higher AM concentrations in plasma compared to nor-
motensive control subjects (Ishimitsu et al., 1994).
Since cultured endothelial and vascular smooth muscle
cells posses specific receptors for this peptide (Ishizaka
et al., 1994; Kato et al., 1995), it is fair to speculate that
the increased AM levels in plasma of pregnant women
might also be involved in reducing the maternal vas-
cular resistance and mean arterial pressure during
normal pregnancy, as well as regulating fetal and fe-
toplacental circulations. Physiological data in support
of this view have come from a recent study using a
model of hypertensive pregnant rats (Makino et al.,
1999b). In this study, the elevated blood pressure and
increased fetal mortality could be reversed by low-dose
administration of AM in late gestation, therefore sug-
gesting that AM plays an important role in the regu-
lation of blood pressure, the blood supply to the utero-
placental unit, and fetal development in late gestation
(Makino et al., 1999b). Other studies have also shown,
however, that despite the elevated AM levels during
pregnancy, the augmented depressor responsiveness to
AM in late pregnant rats seems to be at least partially
mediated by an increase in AM receptor density
(Makino et al., 1999a). Additionally, it has also been
shown that active metabolites of progesterone contrib-
ute to the stimulation of AM release during pregnancy
(Jerat and Kaufman, 1998), which again is consistent
with the role of AM as an endogenous modulator of
vascular adaptation to pregnancy in association with
the involvement of other hormones.
AM in Milk. Milk is known to contain several pep-
tide hormones and growth factors including insulin,
transferrin, lactoferrin, EGF, TGF, nerve growth fac-
tor, and IGF-I and II (Grosvenor et al., 1993;
Koldovsky, 1992). These bioactive compounds are
thought to play critical roles in the growth and devel-
opment of the neonate, participating in physiological
processes such as modulation of gastrointestinal func-
tions, microbial growth control, and immunoregula-
tion. AM was found to be expressed in the epithelium of
mouse mammary gland, and also the fully processed
AM peptide (Mr 6,000) was identified in milk extracts
from lactating mice glands (Ja¨hnke et al., 1997). Im-
munoreactive AM is also present in bovine and human
milk, and human AM concentrations range between
140 to 404 pg/ml, without an apparent pattern of
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change during the progression of lactation (Pı´o et al.,
2000). Interestingly, AM in human milk exerted
growth-promoting activity on a human intestinal cell
line, which could be consistent with a putative role of
this peptide in the regulation of secretor and motor
functions in the gastrointestinal tract, as well as in the
development and maturation of the intestinal epithe-
lium in the period following birth (Pı´o et al., 2000).
Other possible functions of AM in milk, such as patho-
gen protection (antimicrobial activity), modulation of
tissue growth and development, or regulation of the
immune system of the newborn, are still to be investi-
gated.
AM and Perinatal Adaptation
In the fetus, since gas exchange occurs in the pla-
centa, fetal pulmonary vascular resistance is high and
pulmonary blood flow low, merely supplying nutri-
tional requirements for lung growth and some meta-
bolic functions. However, at the time of birth, with
ventilation assumed by the lungs, dramatic changes in
pulmonary circulation occur: pulmonary vascular re-
sistance falls rapidly and pulmonary arterial blood flow
increases approximately 8- to 10-fold (Heymann, 1999;
Heymann and Soifer, 1989; Teitel et al., 1990). The
control of the pulmonary vascular tone both in the fetus
and during the transitional period to air-breathing is
dependent on a complex and interactive group of mech-
anisms, including mechanical influences (e.g., endothe-
lial shear stress, physical expansion, alveolar pO2) and
a variety of endogenous vasoactive substances pro-
duced by the pulmonary vascular endothelium and re-
leased locally or into the circulation. Some of these
vasoactive compounds are known to mediate in part
the pulmonary blood flow in these critical periods: bra-
dykining, acetylcholine, prostacyclin, leukotrienes, ni-
tric oxide, adenosine (Heymann, 1999; Ziegler et al.,
1995).
In adult animals, several studies have demonstrated
that AM produces vasodilatation in pulmonary circu-
lation (Cheng et al., 1994; Heaton et al., 1995; Lippton
et al., 1994). Very interestingly, AM was demonstrated
to significantly increase pulmonary blood flow in late
gestation fetal lambs, reaching levels equal to those
normally achieved postnatally (de Vroomen et al.,
1997). Besides, this AM-induced increase in pulmonary
blood flow has mechanistically been characterized to
depend largely on NO release and partly on KATP chan-
nel activation (Takahashi et al., 2000). These data are
currently raising interest in AM as a candidate for the
maintenance of fetal vascular pulmonary tone, as well
as playing a role in the process of perinatal adaptation
to air breathing (Rudolph, 1998). Some other evidence
has also been interpreted to be consistent with this
hypothesis: (1) AM levels in umbilical blood are similar
to those found in adult plasma and may affect the fetus
and neonate pulmonary vascular tone (Di Iorio et al.,
1999; Hoeldtke et al., 1998); (2) in neonatal piglets,
pulmonary AM clearance appears to be increased, thus
suggesting a physiological role in mediating pulmonary
vasodilation at birth (Sabates et al., 1996).
AM in Gestational Pathologies
As reviewed above, AM levels in fetoplacental tis-
sues, uterus, maternal and umbilical plasma, and am-
niotic fluid are highly increased during normal gesta-
tion. These high AM levels together with some physi-
ological data seem to be indicative of AM implication in
maternal vascular adaptation to pregnancy, as well as
of AM contribution to the regulation of placental and
fetus vascular tone. In addition, AM and at least one of
its receptors are expressed in a very defined spatio-
temporal manner in a great variety of embryonic tis-
sues, also suggesting its role as a growth and differen-
tiation regulator (Montuenga et al., 1997). Taking all
this into consideration, it is reasonable to speculate
that alterations in the expression of AM or its receptors
may be implicated in the pathogenesis of various preg-
nancy related syndromes. In fact, this hypothesis has
been the subject of several investigations, evaluating
the expression of AM and/or AM receptors in placenta,
fetal membranes, and biologic fluids from patients with
pregnancy loss or complications as compared to tissues
from normal term pregnancies. So far, gestational pa-
thologies such as preeclampsia, intrauterine growth
restriction, gestational diabetes mellitus, and hydrops
fetalis have been studied. However, the question
whether altered expression of AM is a primary event or
a secondary compensatory result of abnormal expres-
sion of other factors in many of these pregnancy disor-
ders is far from being well understood, and will require
further studies.
AM in Preeclampsia. Preeclampsia is a major
cause of maternal and neonatal morbidity and mortal-
ity, but despite its public health impact, the etiology of
this disorder is not well established. It has been sug-
gested that failure of trophoblast invasion of the ma-
ternal placental bed may be responsible for impaired
placental perfusion (Dekker and Sibai, 1998; Patrick
and Roberts, 1999). Another key feature of preeclamp-
sia is that endothelial cells are observed to be disrupted
histologically (Khong et al., 1992) and functionally
(Roberts, 1999); since endothelium has an essential
role in the maintenance of a low vascular resistance in
normal pregnancy through the release of several vaso-
active agents, an abnormal endothelial function in pre-
eclampsia could contribute to an increase in vascular
resistance (Roberts et al., 1989).
Some controversy, however, has arisen from discor-
dances in data of different groups studying AM impli-
cation as a pathophysiogical substance in preeclampsia
(Di Iorio et al., 1998a): (1) some groups have not found
a significant difference in maternal plasma AM concen-
tration between preeclamptic and normotensive preg-
nant women (Di Iorio et al., 1998c; Jerat et al., 2001;
Makino et al., 1999c; Minegishi et al., 1999), whereas
others have reported a significant maternal plasma
decrease in patients with preeclampsia as compared to
normal pregnancies (Hata et al., 1997); (2) concerning
AM immunoreactivity in fetoplacental structures from
pregnancies with preclampsia, AM staining has either
been found to be significantly decreased (specifically in
villous syncytiotrophoblasts) with respect to normoten-
sive pregnancies (Kanenishi et al., 2000), or to be in-
creased in the fetal membranes and umbilical artery
(Makino et al., 1999c) as compared to controls. Other
studies did not find variations in AM immunoreactivity
or between both groups (Di Iorio et al., 1998c); (3)
finally, with regard to umbilical vein blood and amni-
otic fluid, AM levels were reported to be significantly
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increased in preeclamptic pregnant women (Di Iorio et
al., 1997b), which suggests that increased AM concen-
trations might be necessary to maintain placental vas-
cular resistance at a physiological level.
Some of the discrepancies in these results could be
explained by methodological differences between
groups, such as different commercial radioimmunoas-
say kits or the use of different polyclonal antibodies in
immunohistochemical staining (Hinson et al., 2000).
Other differences may arise from heterogeneity at sam-
pling or by different criteria in the definition of pre-
eclamptic disorder (Di Iorio et al., 1998a). Possible
interaction of AM with other vasoactive agents as a
fetal response to compromised intrauterine environ-
ment should also be considered. Besides, the presence
and distribution of the different AM receptors and
RAMPs have yet to be established in normal fetopla-
cental tissues, and molecular alterations or changes in
the expression of these receptors could also be impli-
cated in the patophysiology of preclampsia. Some re-
cent data, however, seem to discard this last proposal,
since the increased vascular resistance of preeclamptic
placentas was not due to either reduced AM secretion
nor to an attenuated vascular responsiveness, thus
indicating that AM vasorelaxant pathway is intact in
preeclamptic placentas (Jerat et al., 2001).
AM in Intrauterine Growth Restriction. AM lev-
els were found to be significantly increased in umbilical
plasma of patients with intrauterine growth restriction
(IUGR) as compared to control subjects (Di Iorio et al.,
2000). This syndrome is associated with an impairment
in uteroplacental blood flow (that may be reduced up to
50%) and increased placental resistance, which leads to
a persistent suppression of the fetus growth potential
in response to reduction in substrate supply (Bates et
al., 1996). The increased concentrations of AM in the
circulation of IUGR fetuses are interpreted as a com-
pensatory mechanism to the reduced uteroplacental
flow caused by the altered production of other vasoac-
tive agents, so that placental vascular resistance
and/or fetal circulation would be maintained at physi-
ologic levels (Di Iorio et al., 2000). For instance, levels
of vasoactive molecules such as prostacyclin, nitric ox-
ide, or atrial natriuretic peptide have also been re-
ported to be altered in this type of pathology (Di Iorio et
al., 1997a; Kingdom et al., 1992; Stuart et al., 1981),
and AM could act as a paracrine regulator through the
inhibition or stimulation of these factors. A correlation
between umbilical AM concentrations in IUGR fetuses
and the fetal cerebral/peripheral vessel ratio was also
found; this fact suggested a potential role of AM in
preferentially dilating cerebral vessels, in order to sup-
press the reduction of regional cerebral blood flow and
prevent ischemic brain injury in IUGR (Di Iorio et al.,
2000).
AM in Preterm Labor. The increased expression of
AM mRNA and AM-binding sites in the pregnant rat
uterus relative to nonpregnant rats suggested that this
organ could be a source for the elevated AM maternal
plasma levels in pregnancy, and, additionally, that AM
in the uterus could also play a role in the control of
uterine vascular or nonvascular smooth muscle (Upton
et al., 1997). Alternatively, AM could also indirectly
affect myometrial contractility during pregnancy by its
action on other modulators (such as corticotropin-re-
leasing hormone, adrenocorticotropin, prostaglandins,
nitric oxide, endothelin), contributing to the control of
human parturition (Di Iorio et al., 1998b). In fact, pre-
liminary studies on rat uteri showed a vasorelaxant
role for AM by inhibition of the galanin-induced con-
traction of uterine smooth muscle preparations (Upton
et al., 1997). However, Marinoni et al. (1999) reported
that AM concentrations in amniotic fluid were signifi-
cantly elevated in cases of preterm delivery (premature
rupture of membranes and preterm labor unresponsive
to tocolysis), suggesting that elevated AM levels could
be associated with uterine contractility. As suggested,
this hypothesis requires further investigation, since
the increased concentrations of AM in the amniotic
fluid could derive from enhanced synthesis of AM by
placenta and fetal membranes stimulated by bacterial
products frequently associated with preterm labor, or
alternatively, might reflect a compensatory effect of
AM for the increased synthesis and release of other
uterotonin substances in this situation (Di Iorio et al.,
1998b; Marinoni et al., 1999).
AM in Gestational Diabetes Mellitus. The patho-
genesis of gestational diabetes mellitus (GDM) appears
to involve poor -cell compensation for the insulin re-
sistance that develops in pregnancy, and the majority
of pregnant women suffering from GDM have a quan-
titative defect in insulin secretion (Buchanan et al.,
1990). Since AM was characterized as an inhibitor of
insulin secretion in the islets both in vivo and in the
whole animal (Martı´nez et al., 1996), the possible con-
tribution of AM as a factor leading to hyperglicemia in
GDM was investigated. When AM plasma levels be-
tween pregnant women with or without GDM were
compared, no significant difference was found, al-
though a small subset of women with GDM had higher
AM levels than any normal pregnant women (Martı´nez
et al., 1999). These data seemed to indicate that AM is
not a common contributor to the -cell dysfunction in
GDM, although it may contribute to it in a subset of
women with very high AM levels. Further studies with
long-term follow-up for the development of diabetes
after pregnancy are needed to further clarify the pos-
sible contribution of AM to this -cell dysfunction
(Martı´nez et al., 1999).
AM and Hydrops Fetalis. The abundant expres-
sion of AM in the placenta and in the early developing
heart and blood vessels as well as other fetal organs
predicted that a functional study via AM gene ablation
in mice could have problems of early in utero lethality.
This is in fact what has happened. The two groups that
have attempted the development of an AM knock-out
mouse have found that 100% of AM/mice die before
birth. In particular, Caron and Smithies (2001) per-
formed a study published in a peer-reviewed journal
and described that these knock-out mice die at mid-
gestation (between E13.5 and E14.5), presenting a very
severe and generalized hydrops fetalis and several car-
diovascular abnormalities including overdeveloped
ventricular trabeculae and underdeveloped vascular
smooth muscle in the large arteries. Caron and Smith-
ies (pages 55–59, this issue) summarize the lessons
that have been learnt from AM knock-out and trans-
genic mice about the functions of AM during embryonic
development.
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The severity of the massive generalized edema in AM
/ embryos led Caron and Smithies (2001) to propose
a genetically determined deficiency of AM as one of the
possible causes of nonimmune hydrops fetalis (NIHF)
in humans. NIHF is the result of an increase in inter-
stitial fluid volume, characterized by ascites and pleu-
ral effusions. Nowadays, this syndrome remains a sig-
nificant cause of human fetal and neonatal mortalility
(White, 1999), and chromosome abnormalities, infec-
tions, cardiovascular defects, or extreme lysosomal dis-
orders have been found among the most likely causes of
this disorder (Lallemand et al., 1999; White, 1999).
Despite the many factors known to contribute to the
development of hydrops, the pathogenesis of this con-
dition, however, ultimately involves dysfunctional reg-
ulation of the fluid balance between vascular and in-
tersitital compartments, e.g., changes in capillary and
tissue hydrostatic and oncotic pressures, changes in
capillary permeability, or as also suggested for the AM
knockout embryo, impaired lymphatic drainage proba-
bly due to abnormalities in lymphatic vessel develop-
ment (Caron and Smithies, 2001). Some studies have
also implicated renal function impairment with the
pathogenesis of hydrops fetalis, and, in fact, fetuses in
which the ureters were bilaterally ligated developed
this syndrome (Gibson and Lumbers, 1996). In relation
to renal function, AM has been associated with diuretic
and natriuretic activities (Ebara et al., 1994; Vari et
al., 1996), and thus absence of this peptide could also
be proposed to lead to inappropriate fetal renal func-
tion and finally contribute to the development of hy-
drops.
In summary, AM has been found to be very widely
expressed during gestation, and similarly to the pluri-
potent characterization of this peptide in adult life, a
broad panel of functions have been proposed also for
AM during fetal development. In this sense, AM has
been found to be expressed in various fetoplacental
structures and maternal decidual cells from early in
embryonic development to pregnancy at term, which is
suggestive of a putative role of this peptide both at
peri-implantation stages and in the regulation of feto-
placental hemodynamics both directly or indirectly
through interaction with other vasoactive factors. Be-
sides, high AM levels in maternal and umbilical
plasma correlate with the implication of AM in vascu-
lar adaptation to pregnancy, and probably also with
the regulation of the fetal vascular tone; the physiolog-
ical significance of AM in amniotic fluid and milk seems
to be more related to maturation processes and with
immunologic protection of the fetus or the newborn.
Additionally, AM has been found to be expressed in a
wide variety of tissues and organs during embryonic
development in a very defined spatio-temporal manner,
which also suggests a role for this peptide in growth
and differentiation processes (for proposed AM func-
tions during pregnancy, see Table 2). However, future
studies need to be undertaken towards the confirma-
tion of many of those proposed functions, especially
with regard to the presence and distribution of differ-
ent AM receptors, and correlation of physiological and
expression studies for this peptide when possible. Fi-
nally, but not least important, the identification of fac-
tor H as an AM binding protein with the ability to
modify AM function, and the presence of factor H in
several fetal structures, open a new investigative ave-
nue in relation to the role of AM both in normal and
pathophysiological states during pregnancy.
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